2016
Therapy-related myelodysplastic syndromes, or are they?
Zahr A, Kavi AM, Mukherjee S, Zeidan AM. Therapy-related myelodysplastic syndromes, or are they? Blood Reviews 2016, 31: 119-128. PMID: 27923516, DOI: 10.1016/j.blre.2016.11.002.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsTherapy-related myelodysplastic syndromeMyelodysplastic syndromeAccurate risk stratificationManagement of patientsCounseling of patientsEffective prevention strategiesForms of MDCurrent clinical toolsRisk stratificationCancer survivorsPrior receiptRadiation monotherapyPatientsPrevention strategiesTherapeutic interventionsClinical decisionClinical toolSyndromeIndividual outcomesDe novoMonotherapyChemotherapyRadiotherapyPrognosticationIncidenceThe Interactions Between Diabetes Mellitus and Myelodysplastic Syndromes: Current State of Evidence and Future Directions.
Hamoudeh E, Zeidan AM, Barbarotta L, Rosano N. The Interactions Between Diabetes Mellitus and Myelodysplastic Syndromes: Current State of Evidence and Future Directions. Current Diabetes Reviews 2016, 12: 231-9. PMID: 26008639, DOI: 10.2174/1573399811666150526151241.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsDiabetes mellitusMyelodysplastic syndromeDiabetic patientsManagement of MDSOutcomes of patientsEnd-organ damageRisk of progressionRisk of complicationsCommon hematologic malignancyIntensive therapeutic interventionMultiple epidemiologic studiesAcute myeloid leukemiaLow blood countsDiabetic controlAdjunct drugsGlucose controlBlood countImportant unmetInsulin resistanceDysplastic changesHematologic malignanciesRisk factorsMyeloid leukemiaEpidemiologic studiesTherapeutic interventions
2015
The evolving field of prognostication and risk stratification in MDS: Recent developments and future directions
Lee EJ, Podoltsev N, Gore SD, Zeidan AM. The evolving field of prognostication and risk stratification in MDS: Recent developments and future directions. Blood Reviews 2015, 30: 1-10. PMID: 26119927, DOI: 10.1016/j.blre.2015.06.004.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsMyelodysplastic syndromeRisk stratificationRecurrent molecular mutationsRisk stratification toolRelevant clinical outcomesPrediction of outcomeRisk/benefit calculationsClinical courseClinical outcomesStratification toolMDS patientsPrognostication toolsIndividual patientsClinical practiceMolecular testingTherapeutic interventionsPatient careTherapeutic selectionPatientsMolecular mutationsIndependent impactPrognosticationBiological heterogeneityOutcomesReliable assay